Industry Strength Score
36/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NANOBIOTIX SA - ADR (NBTX) Stock Price & Overview
NASDAQ:NBTX • US63009J1079
Current stock price
35.12 USD
+0.5 (+1.44%)
Last:
The current stock price of NBTX is 35.12 USD. Today NBTX is up by 1.44%. In the past month the price increased by 13.14%. In the past year, price increased by 951.18%.
NBTX Key Statistics
52-Week Range3.26 - 41.8899
Current NBTX stock price positioned within its 52-week range.
1-Month Range29.01 - 35.94
Current NBTX stock price positioned within its 1-month range.
- Market Cap
- 1.703B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.58
- Dividend Yield
- N/A
NBTX Stock Performance
Today
+1.44%
1 Week
+4.59%
1 Month
+13.14%
3 Months
+67.24%
Longer-term
6 Months +68.28%
1 Year +951.18%
2 Years +398.86%
3 Years +666.81%
5 Years +105.14%
10 Years N/A
NBTX Stock Chart
NBTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NBTX. When comparing the yearly performance of all stocks, NBTX is one of the better performing stocks in the market, outperforming 99.63% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NBTX. NBTX has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NBTX Earnings
On March 31, 2026 NBTX reported an EPS of -0.39 and a revenue of 5.96M. The company missed EPS expectations (-170.16% surprise) and missed revenue expectations (-90.05% surprise).
Next Earnings DateMay 19, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-€0.39
Revenue Reported5.955M
EPS Surprise -170.16%
Revenue Surprise -90.05%
NBTX Forecast & Estimates
12 analysts have analysed NBTX and the average price target is 38.44 USD. This implies a price increase of 9.45% is expected in the next year compared to the current price of 35.12.
For the next year, analysts expect an EPS growth of -24.95% and a revenue growth 9.99% for NBTX
Analysts
Analysts85
Price Target38.44 (9.45%)
EPS Next Y-24.95%
Revenue Next Year9.99%
NBTX Financial Highlights
Over the last trailing twelve months NBTX reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 65.28% compared to the year before.
Income Statements
Revenue(TTM)7.84M
Net Income(TTM)-23.96M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.36% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%60.2%
Sales Q2Q%136.13%
EPS 1Y (TTM)65.28%
Revenue 1Y (TTM)167.56%
NBTX Ownership
Ownership
Inst Owners30.68%
Shares48.50M
Float40.59M
Ins Owners0.63%
Short Float %0.03%
Short Ratio0.18
NBTX Industry Overview
NBTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
21%
Outperformed 21% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.6
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
NBTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NBTX
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
IPO: 2012-10-29
NANOBIOTIX SA - ADR
60 rue de Wattignies
Paris ILE-DE-FRANCE 75012 FR
CEO: Dr. Laurent Levy
Employees: 103
Phone: 33140260470
NANOBIOTIX SA - ADR / NBTX FAQ
What does NANOBIOTIX SA - ADR do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Can you provide the latest stock price for NANOBIOTIX SA - ADR?
The current stock price of NBTX is 35.12 USD. The price increased by 1.44% in the last trading session.
Does NBTX stock pay dividends?
NBTX does not pay a dividend.
How is the ChartMill rating for NANOBIOTIX SA - ADR?
NBTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists NBTX stock?
NBTX stock is listed on the Nasdaq exchange.
How is the valuation of NANOBIOTIX SA - ADR (NBTX) based on its PE ratio?
NANOBIOTIX SA - ADR (NBTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
Who owns NANOBIOTIX SA - ADR?
You can find the ownership structure of NANOBIOTIX SA - ADR (NBTX) on the Ownership tab.